Drug Class |
Aminoglycoside antibiotic |
Tetracycline antibiotic |
Mechanism of Action |
Inhibits bacterial protein synthesis |
Inhibits bacterial protein synthesis |
Spectrum of Activity |
Gram-negative bacteria (including Pseudomonas aeruginosa) |
Broad-spectrum activity against both Gram-positive and Gram-negative bacteria, as well as some protozoa |
Common Uses |
Treatment of severe bacterial infections, particularly those caused by multidrug-resistant Gram-negative bacteria |
Treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, and skin infections |
Route of Administration |
Intravenous, inhalation, topical (eye drops) |
Oral, topical (ointment, eye ointment), injection (for veterinary use) |
Resistance Concerns |
Resistance can develop over time with prolonged use |
Resistance can develop over time with prolonged use |
Adverse Effects |
Nephrotoxicity, ototoxicity (ear toxicity), neuromuscular blockade (with high doses) |
Gastrointestinal disturbances, photosensitivity (increased sensitivity to sunlight), allergic reactions |
Precautions/Warnings |
Requires monitoring of kidney function and hearing during treatment |
Avoid use in children under 8 years old (may cause tooth discoloration), caution in patients with liver or kidney impairment, may reduce effectiveness of oral contraceptives |
Drug Interactions |
Can interact with other medications that affect kidney function or cause hearing damage |
Can interact with other medications, antacids, and supplements that may reduce its absorption |
Pregnancy Category |
Category D (may cause harm to the fetus) |
Category D (may cause harm to the fetus) |
Trade Names |
Tobrex, Nebcin |
Terramycin, Oxytetracycline |